PMID- 31483891
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 1651-2227 (Electronic)
IS  - 0803-5253 (Linking)
VI  - 109
IP  - 3
DP  - 2020 Mar
TI  - Young children with moderate-to-severe atopic dermatitis can be treated safely 
      and effectively with either topical tacrolimus or mild corticosteroids.
PG  - 550-556
LID - 10.1111/apa.15001 [doi]
AB  - AIM: We collected evidence and safety data for topical tacrolimus in small 
      children with atopic dermatitis (AD) and compared the usage with topical 
      corticosteroid. METHODS: This was an interim analysis of 75 patients (55% female) 
      at 1 year of an ongoing 3-year randomised open-label comparative follow-up study 
      of topical tacrolimus vs corticosteroid treatment. One- to three-year-old 
      children with moderate-to-severe eczema referred to the Skin and Allergy Hospital 
      in Helsinki, Finland, were enrolled. RESULTS: Efficacy parameters, the Eczema 
      Area and Severity Index (EASI), Investigator's Global Assessment (IGA), 
      transepidermal water loss (TEWL), eczema area, serum total immunoglobulin E (IgE) 
      and the blood eosinophil count, showed improvement in both groups during the 
      study. However, patients with signs of early sensitisation at baseline (elevated 
      serum total IgE, elevated eosinophil count, positive prick tests or specific IgEs 
      to aero or food allergens) had statistically significantly lower TEWL at the 
      eczema site and a smaller eczema area at 12 months in the tacrolimus group. No 
      severe adverse effects were seen during the treatment. CONCLUSION: Children with 
      AD and signs of early sensitisation appeared to benefit more from early 
      tacrolimus than corticosteroid treatment. Small children may need stronger but 
      nevertheless safe ointment options when treating moderate-to-severe AD.
CI  - (c) 2019 Foundation Acta Paediatrica. Published by John Wiley & Sons Ltd.
FAU - Perala, Miia
AU  - Perala M
AUID- ORCID: 0000-0003-3794-3515
AD  - University of Helsinki and Helsinki University Hospital, Skin and Allergy 
      Hospital, Helsinki, Finland.
FAU - Ahola, Maria
AU  - Ahola M
AD  - University of Helsinki and Helsinki University Hospital, Skin and Allergy 
      Hospital, Helsinki, Finland.
FAU - Mikkola, Tytti
AU  - Mikkola T
AD  - University of Helsinki and Helsinki University Hospital, Skin and Allergy 
      Hospital, Helsinki, Finland.
FAU - Pelkonen, Anna S
AU  - Pelkonen AS
AD  - University of Helsinki and Helsinki University Hospital, Skin and Allergy 
      Hospital, Helsinki, Finland.
FAU - Remitz, Anita
AU  - Remitz A
AD  - University of Helsinki and Helsinki University Hospital, Skin and Allergy 
      Hospital, Helsinki, Finland.
FAU - Makela, Mika J
AU  - Makela MJ
AD  - University of Helsinki and Helsinki University Hospital, Skin and Allergy 
      Hospital, Helsinki, Finland.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20191007
PL  - Norway
TA  - Acta Paediatr
JT  - Acta paediatrica (Oslo, Norway : 1992)
JID - 9205968
RN  - 0 (Adrenal Cortex Hormones)
RN  - 0 (Immunosuppressive Agents)
RN  - WM0HAQ4WNM (Tacrolimus)
SB  - IM
MH  - Administration, Topical
MH  - Adrenal Cortex Hormones/therapeutic use
MH  - Child, Preschool
MH  - *Dermatitis, Atopic/drug therapy
MH  - *Eczema/drug therapy
MH  - Female
MH  - Finland
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Infant
MH  - Male
MH  - Tacrolimus/therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - atopic dermatitis
OT  - child
OT  - corticosteroid
OT  - sensitisation
OT  - tacrolimus
EDAT- 2019/09/05 06:00
MHDA- 2021/05/15 06:00
CRDT- 2019/09/05 06:00
PHST- 2019/05/28 00:00 [received]
PHST- 2019/07/02 00:00 [revised]
PHST- 2019/09/03 00:00 [accepted]
PHST- 2019/09/05 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2019/09/05 06:00 [entrez]
AID - 10.1111/apa.15001 [doi]
PST - ppublish
SO  - Acta Paediatr. 2020 Mar;109(3):550-556. doi: 10.1111/apa.15001. Epub 2019 Oct 7.